1531-8249/asset/olbannerleft.gif?v=1&s=d36d5ebb3caa1b29d7f078a97c52973b0963daf2)
1531-8249/asset/olbannerright.gif?v=1&s=078041b213f6959d63575a593f880457c45116f0)
Brief Communications
Valproate therapy and nonalcoholic fatty liver disease
Article first published online: 25 MAR 2004
DOI: 10.1002/ana.20074
Copyright © 2003 American Neurological Association
1531-8249/asset/cover.gif?v=1&s=685ec69724c5ed4c8847ce939e70ceb45065856f "Annals of Neurology")
Additional Information
How to Cite
Luef, G. J., Waldmann, M., Sturm, W., Naser, A., Trinka, E., Unterberger, I., Bauer, G. and Lechleitner, M. (2004), Valproate therapy and nonalcoholic fatty liver disease. Annals of Neurology, 55: 729–732. doi: 10.1002/ana.20074
Publication History
- Issue published online: 21 APR 2004
- Article first published online: 25 MAR 2004
- Manuscript Accepted: 22 JAN 2004
- Manuscript Revised: 1 DEC 2003
- Manuscript Received: 16 SEP 2003
- Abstract
- Article
- References
- Cited By
Abstract
Nonalcoholic fatty liver disease was defined recently as another symptom of insulin resistance. Continuous therapy with valproate can result in increased body weight and insulin resistance, but no data are yet available on a possible relationship between valproate and nonalcoholic fatty liver disease. We here demonstrate in abdominal ultrasound investigations that characteristics of fatty liver disease were present in 61% of valproate-treated patients as compared with 23% receiving carbamazepine therapy. Ann Neurol 2004